Evidence map›Paper›PMID 40376568›Full record

ReviewDigital health

Nanobiosensors in neurodegenerative disease diagnosis: A promising pathway for early detection.

Shikha Yadav, Sarad Pawar Naik Bukke, Shatrudhan Prajapati, Ajay Pal Singh, Ananda Kumar Chettupalli, Buyinza Nicholas

Abstract readReview
In one paragraph

Review in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shikha YadavDepartment of Pharmaceutical Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Sarad Pawar Naik BukkeDepartment of Pharmaceutics and Pharmaceutical Technology, Kampala International University, Ishaka-Bushenyi, Uganda.ORCID https://orcid.org/0000-0002-5693-2953
Shatrudhan PrajapatiSchool of Pharmacy, Lingaya's Vidyapeeth, Faridabad, Haryana, India.
Ajay Pal SinghSchool of Pharmacy, Lingaya's Vidyapeeth, Faridabad, Haryana, India.
Ananda Kumar ChettupalliDepartment of Pharmaceutical Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India.
Buyinza NicholasDepartment of Pharmaceutics and Pharmaceutical Technology, Kampala International University, Ishaka-Bushenyi, Uganda.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases, including Alzheimer's and Parkinson's, are characterized by progressive neuronal loss, leading to cognitive and motor impairments. Early diagnosis remains a challenge due to the slow progression of symptoms and the limitations of current diagnostic methods. Nanobiosensors, leveraging the high sensitivity and specificity of nanotechnology, offer a promising, noninvasive, and cost-effective approach for detecting disease biomarkers at ultra-low concentrations. This review highlights recent advancements in nanobiosensor technology, including the integration of gold nanoparticles, quantum dots, and carbon nanotubes, which have significantly enhanced biomarker detection precision. Furthermore, it examines the advantages of nanobiosensors over traditional diagnostic techniques, such as improved sensitivity, rapid detection, and minimal invasiveness. The potential of these innovative sensors to revolutionize early disease detection and improve patient outcomes is discussed, along with existing challenges in clinical translation, including stability, reproducibility, and regulatory considerations. Addressing these limitations will be crucial for integrating nanobiosensors into routine clinical practice and advancing personalized medicine for neurodegenerative disorders.

Indexed as

Alzheimer's diseasebiomarkersbiosensingelectrochemical sensorsnanobiosensorsnanotechnologyNeurodegenerative diseasesParkinson's disease

Identifiers

PMID40376568
PMCPMC12078979

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.